Entera Bio Ltd.
ENTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEntera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. Valued at $96.6M, ENTX is a micro-cap name in its sector. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Market Cap
$96.6M
Beta
1.43
P/E (TTM)
—
P/E (Fwd)
-3.56
EPS (TTM)
$-0.26
EPS (Fwd)
$-0.55
ROE
-82.3%
ROA
-45.0%
Cash
$4.1M
Total Debt
$448,000
Free CF
-$4.8M
52W Change
0.5%
Annual Financials
Cash vs Debt
Where ENTX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ENTX finished 14.08% above its 150-day moving average ($1.42) and 3.57% below its 200-day moving average ($1.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENTX overbought or oversold?
At the July 15, 2026 close, ENTX's RSI(14) was 54.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $4.1M in cash comfortably exceeding the $448K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$4.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -82.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $134K (2022) to $42K (2025), a 69% decline worth watching.
With cash comfortably exceeding debt, ENTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Entera Bio Ltd. and its sector.